Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Market Capitalization: 1.15 B
The data is delayed by 15 minutes.
ACOR is in the long-term down -62% below S&P in 16 years.
Description: Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. The company?s products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; Zanaflex Capsules and Zanaflex tablets, a short-acting drug for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain. It is also involved in developing Diazapam Nasal Spray for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase III clinical development program preparations for post-stroke deficits; NP-1998, a topical solution that is in phase III clinical trail for the treatment of neuropathic pain; AC105, which is in Phase II clinical trials for the treatment of SCI; Neuregulin Program that has completed Phase 1 clinical trial for the trea
|Shares Outstanding||46.07 M||EPS||-1.16||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||2.8%||Sales Growth - Q/Q||-15.29%||P/E||-14.87|
|P/E To EPS Growth||P/S||2.74||P/BV||2.1||Price/Cash Per Share||3.83|
|Price/Free Cash Flow||16.48||ROA||1.26%||ROE||2.53%||ROI||1.53%|
|Current Ratio||3.47||Quick Ratio||3.09||Long Term Debt/Equity||0.96||Debt Ratio||0.22|
|Gross Margin||80.15%||Operating Margin||7.54%||Net Profit Margin||3.3%||Dividend Payout Ratio|
|Cash From Financing Activities||4.63 M||Cash From Investing Activities||-116.04 M||Cash From Operating Activities||-9.25 M||Gross Profit||90.84 M|
|Net Profit||1000 K||Operating Profit||5.69 M||Total Assets||1.1 B||Total Current Assets||408.31 M|
|Total Current Liabilities||460.01 M||Total Debt||292.68 M||Total Liabilities||540.27 M||Total Revenue||113.71 M|
|High 52 week||32.6||Low 52 week||13.8||Last close||32.6||Last change||7.24%|
|RSI||96.12||Average true range||1.73||Beta||1.06||Volume||622.39 K|
|Simple moving average 20 days||27.01%||Simple moving average 50 days||34.29%||Simple moving average 200 days||35.16%|
|Performance Week||23.72%||Performance Month||38.14%||Performance Quart||27.34%||Performance Half||57.11%|
|Performance Year||92.9%||Performance Year-to-date||51.98%||Volatility daily||2.78%||Volatility weekly||6.22%|
|Volatility monthly||12.76%||Volatility yearly||44.18%||Relative Volume||329.71%||Average Volume||497.09 K|
|New High||New Low|
2020-06-04 11:31:03 | Acorda ACOR Down 11.8% Since Last Earnings Report: Can It Rebound?
2020-06-03 09:05:01 | Acadia Healthcare Ties Up for Improved Behavioral Services
2020-05-06 13:27:05 | Acorda ACOR Q1 Earnings Lag Estimates, Revenues Fall Y/Y
2020-05-05 18:15:10 | Acorda Therapeutics ACOR Reports Q1 Loss, Misses Revenue Estimates
2020-05-05 16:00:00 | Acorda Reports First Quarter 2020 Financial Results and Provides Business Update
2020-04-28 07:00:00 | Acorda First Quarter 2020 Update: Webcast/Conference Call Scheduled for May 5, 2020
2020-04-24 11:49:03 | Acorda ACOR to Report Q1 Earnings: What's in the Cards?
2020-04-16 17:45:09 | Acorda Therapeutics ACOR Flat As Market Gains: What You Should Know
2020-04-07 17:50:09 | Acorda Therapeutics ACOR Stock Moves -0.11%: What You Should Know
2020-04-07 12:37:04 | Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study
2020-04-07 11:14:03 | Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue
2020-04-03 08:31:12 | Immunomedics IMMU in Focus: Stock Moves 5% Higher
2020-04-02 10:08:02 | Nabriva NBRV Looks Good: Stock Adds 5.7% in Session
2020-03-30 08:06:12 | New Strong Buy Stocks for March 30th
2020-03-17 12:00:04 | What Makes Acorda ACOR a New Buy Stock
2020-03-14 11:30:03 | Why Is Acorda ACOR Down 54.7% Since Last Earnings Report?
2020-02-24 07:00:00 | Acorda Therapeutics to Present at Cowen Annual Health Care Conference
2020-02-17 21:01:43 | Edited Transcript of ACOR earnings conference call or presentation 13-Feb-20 1:30pm GMT
2020-02-14 11:57:04 | Acorda ACOR Q4 Earnings Top Estimates, Revenues Fall Y/Y
2020-02-13 10:25:03 | Acorda Therapeutics ACOR Reports Q4 Loss, Tops Revenue Estimates
2020-02-13 09:15:02 | Acorda ACOR Beats Earnings & Revenues Estimates in Q4
2020-02-10 10:20:03 | What's in Store for Acorda ACOR This Earnings Season?
2020-02-06 12:31:05 | Earnings Preview: Acorda Therapeutics ACOR Q4 Earnings Expected to Decline
2020-02-06 05:51:23 | Acorda Therapeutics, Inc. NASDAQ:ACOR: What Does Its Beta Value Mean For Your Portfolio?
2020-01-24 08:54:01 | Implied Volatility Surging for Acorda ACOR Stock Options
2020-01-15 07:00:00 | Acorda Provides 2019 Highlights and 2020 Guidance at J.P. Morgan Healthcare Conference
2020-01-08 07:00:00 | Acorda to Present at the 38th Annual J.P. Morgan Healthcare Conference
2020-01-07 10:55:03 | Acorda Therapeutics ACOR in Focus: Stock Moves 5.7% Higher
2019-12-12 10:31:56 | Hedge Funds Are Getting Burned By Acorda Therapeutics Inc ACOR
2019-12-04 11:30:04 | Acorda ACOR Down 13.5% Since Last Earnings Report: Can It Rebound?
2019-12-02 10:22:03 | Acorda ACOR Down More Than 80% Year to Date: Here's Why
2019-11-27 07:00:00 | Acorda Therapeutics Elects John Kelley Chair, Board of Directors
2019-11-12 07:00:00 | Acorda Therapeutics Announces Departure of President, International & General Counsel
2019-11-08 10:21:43 | Is Acorda Therapeutics, Inc.'s NASDAQ:ACOR CEO Paid Enough Relative To Peers?
2019-11-07 11:08:04 | Zoetis ZTS Beats on Earnings in Q3, Reports In-Line Sales
2019-11-07 11:05:04 | Horizon Therapeutics' HZNP Q3 Earnings Beat Estimates
2019-11-07 11:04:04 | Esperion ESPR Reports Wider-Than-Expected Loss in Q3
2019-11-07 08:50:01 | Geron GERN Q3 Earnings Beat Estimates, Stock Gains 4.1%
2019-11-06 16:40:57 | Were Hedge Funds Right About Dumping Acorda Therapeutics Inc ACOR?
2019-11-06 16:28:46 | Edited Transcript of ACOR earnings conference call or presentation 4-Nov-19 9:30pm GMT
2019-11-06 10:56:03 | Perrigo PRGO Beats on Q3 Earnings, Tightens '19 EPS View
2019-11-06 10:34:03 | Intercept ICPT Earnings and Sales Miss Estimates in Q3
2019-11-05 11:45:04 | Acorda ACOR Q3 Earnings and Revenues Surpass Estimates
2019-11-05 11:09:04 | Agenus AGEN Q3 Earnings Beat Estimates, Revenues Up Y/Y